<DOC>
	<DOCNO>NCT02094469</DOCNO>
	<brief_summary>This study conduct accordance local regulation New Drug Application . Overall duration trial 3 year approval MFDS . Each subject participate around 26 week , include 24 week treatment period 2 week safety follow period . Withdrawn subject due efficacy 4 week treatment participate 6 week total include 2 week safety follow . Withdrawn subject reason also 2 week follow period .</brief_summary>
	<brief_title>Safety Efficacy Study Cilostazol Treat Vasospastic Angina</brief_title>
	<detailed_description>A Multicenter , One group , Open-label Study . Cilostazol treat additional 24 week subject complete 021-KOA-1301i study . PletaalÒ ( Cilostazol ) take 100mg oral tablet bid 2 3weeks dosing PletaalÒ ( Cilostazol ) 50mg oral tablet bid 1 week . The dose adjust investigator 's discretion study detail method describe Protocol . Subject 2 chest pain 4th week withdrawn study ( But , subject show 50 % chest pain decrease compare 1st week would withdrawn. ) . Subjects participate trial 2 week follow-up study completion .</detailed_description>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Angina Pectoris , Variant</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1 . Male female subject age 20 80 year , subject whose age time enrollment 80 021KOA1301i clinical trial 81 clinical trial 2 . Subjects complete 021KOA1301i clinical trial 3 . Women childbearing potential negative pregnancy test enrollment agree practice contraceptive measure throughout clinical trial ( e.g. , hormonal contraceptive , intrauterine device , condom + spermicidal agent , diaphragm + spermicidal agent , partner 's infertility ) 4 . Subjects sign write agreement indicate give full explanation clinical trial willing participate clinical trial 1 . Subjects fell one exclusion criterion time enrollment 021KOA1301i 2 . Subjects report follow event , fall exclusion criterion KOA1301i , initiation 021KOA1301i participation enrollment visit 021KOA1302i Myocardial infarction myocardial infarction induce vasospastic angina Lifethreatening vasospastic episode ( e.g. , ventricular tachycardia , ventricular fibrillation , syncope ) Stroke , intracranial hemorrhage , transient ischemic attack ( TIA ) Hemorrhage ( hemophilia , capillary fragility , intracranial hemorrhage , upper gastrointestinal bleeding , urinary tract bleeding , hemoptysis , vitreous hemorrhage , etc . ) 3 . Subjects currently use medication contraindicate 021KOA1301i ( exclude investigational product 021KOA1301i ) baseline 4 . Subjects meet follow criterion baseline laboratory finding severe anemia hemoglobin ≤6.5 g/dl baseline Creatinine level ≥ 1.5 mg/dL baseline AST ALT &gt; 3x ULN baseline Platelet count &lt; 100,000mm3 baseline 5 . Pulse rate exceed 100 bpm measure vital sign baseline : Tachycardia 6 . Hypotension systolic pressure &lt; 90mmHg baseline 7 . Uncontrolled hypertension define systolic pressure ≥ 160 mmHg diastolic pressure ≥ 100 mmHg baseline 8 . QT prolongation define QTcB &gt; 450 msec men QTcB &gt; 470 msec woman baseline 9 . Women childbearing potential positive pregnancy test baseline 10 . Women agree practice contraceptive measure , pregnant lactate 11 . Subjects expect potential benefit additional administration Cilostazol , accord investigator 's judgment 12 . Subjects otherwise judge investigator inappropriate inclusion trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Treatment vasospastic angina</keyword>
</DOC>